|

Samuraciclib Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Also known as: CDK7 Inhibitor CT7001, CT 7001, CT-7001, CT7001, ICEC0942

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • University of Washington1
  • Hoffmann-La Roche1

Indications

  • Cancer2
  • Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1
  • Locally Advanced Pancreatic Ductal Adenocarcinoma1
  • Resectable Pancreatic Ductal Adenocarcinoma1
  • Borderline Resectable Pancreatic Ductal Adenocarcinoma1

Duarte, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2

Seattle, Washington1 trial

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.